New cardiac devices are small enough to be delivered through blood vessels into the heart.
Pacemaker surgery typically requires a doctor to make an incision
above a patient’s heart, dig a cavity into which they can implant the
heartbeat-regulating device, and then connect the pulse generator to
wires delivered through a vein near the collarbone. Such surgery could
soon be completely unnecessary. Instead, doctors could employ
miniaturized wireless pacemakers that can be delivered into the heart
through a major vein in the thigh.
On Monday, doctors in Austria
implanted one such device into a patient—the first participant in a
human trial of what device-manufacturer Medtronic
says is the smallest pacemaker in the world. The device is 24
millimeters long and 0.75 cubic centimeters in volume—a tenth the size
of a conventional pacemaker. Earlier this year, another device
manufacturer, St. Jude Medical,
bought a startup called Nanostim that makes another tiny pacemaker, and
St. Jude is offering it to patients in Europe. This device is 41 millimeters long and one cubic centimeter in volume.
Doctors
can implant such pacemakers into the heart through blood vessels, via
an incision in the thigh. They use steerable, flexible tubes called
catheters to push the pacemakers through a large vein.
The two new
devices are the latest effort to make heart surgery less traumatic.
Doctors began to widely use less invasive heart treatments in the late
1990s, when artery-unclogging balloons delivered by catheters started to
replace bypass surgeries. Other cardiac technologies like stents, which
prop open weak or narrow arteries, can also be delivered through blood
vessels. More recently, researchers have developed artificial valves for
patients whose natural valves have become damaged; these devices can
also be delivered by catheters snaking through large blood vessels.
Brian Lindman,
a cardiovascular specialist at Washington University School of
Medicine, and colleagues have found that less invasive catheter-based
procedures for valve repair can be safer for high-risk elderly patients
and can enable doctors to treat patients who are too frail to undergo
surgery. More recently, Lindman published a study
suggesting that the transcatheter method may improve the odds of
survival for diabetic patients as well. However, for some cardiac
treatments such as valve repair, a more invasive surgery enables
longer-lasting repairs, and so may be the better option for patients
strong enough for surgery. “Surgery or transcatheter is not always
better,” says Lindman. “It depends on the cardiac problem and on the
nuances of each procedure.”
Both tiny pacemakers are now being tested in human trials, and St.
Jude’s has been approved for use in patients in Europe. The device
manufacturers say the batteries in the tiny pacemakers will last up to
eight or 10 years when running at full-stimulating capacity. The new
pacemakers are also “leadless”—that is, they don’t require long
electrodes winding their way into heart. Instead, they sit inside the
heart and deliver electric pulses through small prongs that touch the
heart. This new design reduces the amount of power required by the
device and eliminates a major source of device failure (see “A Pacemaker the Size of a Tic Tac”).
Medtronic
has also developed a miniaturized cardiac monitor for patients with
arrhythmias or undiagnosed heart problems. Cardiac monitors continuously
track heart activity; patients undergoing testing may have to wear a portable device
around their neck, which hooks up to wires from several electrodes
stuck to the chest, perhaps for days at a time. Doctors can implant
Medtronic’s new monitor using a syringe-like system that inserts the
device into a small incision above the heart that is just eight
millimeters deep. The monitor can then wirelessly transmit heartbeat
data to a bedside monitor or potentially even to a smart phone, says
Mark Phelps, an engineer leading Medtronic’s miniaturization efforts.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment